Resveratrol and Diabetic Retinopathy
Could a multi-target molecule be used for earlier intervention of DR?
Recent advancements in diabetic retinopathy (DR) treatments focus on reactive therapy, notably anti-VEGF injections and laser photocoagulation. However, these methods fall short in addressing early neuroinflammatory and metabolic disruptions that precede significant vascular damage. A systematic review emphasizes resveratrol, a polyphenol with antioxidant properties, as a multi-target modulator that may influence mitochondrial health and inflammatory signaling in early DR, thus holding potential for upstream intervention strategies. While preclinical studies hint at the efficacy of resveratrol, extensive human trials are required to confirm its clinical applicability.
1. Diabetic retinopathy treatments are mainly reactive. 2. Resveratrol is identified as a potential multi-target modulator for early DR. 3. It influences mitochondrial health, inflammatory signaling, and neuroglial behavior. 4. Resveratrol has shown protective effects on retinal structure in preclinical studies. 5. Its anti-inflammatory properties involve suppression of multiple mediators. 6. Current evidence for resveratrol is preclinical and not yet suitable for clinical use.
